Aclaris Therapeutics vs Zenas BioPharma
ACRS and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and ZBIO compare
Zenas BioPharma is the larger company, worth 3.6 times as much as Aclaris Therapeutics ($1.8B against $498M).
Aclaris Therapeutics scores higher on the StockData Score (5 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | ZBIO |
|---|---|---|
| Size and price | ||
| Market cap | $498M | $1.8B |
| Share price | $3.38 | $27.75 |
| Change, 1 year | 34.1% | −20.7% |
| Change, 5 years | −73.2% | – |
| Beta (5Y) | 1.04 | 0.25 |
| Employees | 73 | 167 |
| StockData Score | ||
| Total score | 5 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 60.5× | – |
| P/B | 4.0× (better) | 8.5× |
| FCF yield | −12.5% (better) | −13.4% |
| Fair value | $1.42 | – |
| Margin of safety | −138% | – |
| Growth | ||
| Revenue growth (TTM) | −51.0% | – |
| Revenue growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 79.5% | – |
| Operating margin | −1050% | – |
| Net margin | −921% | – |
| FCF margin | −757% | – |
| Return on equity | −59.1% (better) | −265% |
| Financial health | ||
| Debt / equity | 0.00 | 1.05 (better) |
| Current ratio | 3.46 | 9.42 (better) |
| Altman Z-score | −3.52 | −1.48 (better) |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 94.0% |
| Held by insiders | 13.3% | 36.1% |
| Insider net buying, 12 months | −$1.4M | $11.4M (better) |
| Short interest, % of float | 9.1% | 27.3% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- ZBIO stock overview
- ZBIO income statement
- ZBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.